Breast Cancer

Adding Ribociclib to Endocrine Therapy May Reduce Recurrence Risk in Patients With Hormone Receptor–Positive, HER2-Negative Early-Stage Breast Cancer

Adding the CDK4/6 inhibitor ribociclib to endocrine therapy resulted in a significant improvement in invasive disease–free survival...

Gynecologic Cancers

Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer

Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer...

Gynecologic Cancers

Addition of Olaparib and Durvalumab to Standard of Care May Prolong Progression-Free Survival in Patients With Advanced Ovarian Cancer

Patients with newly diagnosed advanced ovarian cancer without a BRCA mutation who received durvalumab and olaparib in addition to the...

Hepatobiliary Cancer

Zanidatamab Shows Activity in Refractory HER2-Amplified Biliary Tract Cancer

The HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2-positive...

CNS Cancers

Is Pembrolizumab Effective in Patients With Brain Metastases?

In a phase II clinical trial, investigators found that 42% of patients with brain metastases benefited from treatment with...


Prostate Cancer

Neeraj Agarwal, MD, on Prostate Cancer: Androgen-Deprivation Therapy With Orteronel or Bicalutamide

Gynecologic Cancers

OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer

Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lung Cancer

Byoung Chul Cho, MD, PhD, on NSCLC: Amivantamab Plus Lazertinib for Treatment of Relapsed Disease

Kidney Cancer

No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...

Bladder Cancer

CheckMate 274: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma

As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo among all patients with high-risk muscle-invasive urothelial carcinoma who...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment


Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML

As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...